Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial

Introduction Diabetic kidney disease (DKD) is the most frequent cause of end-stage renal disease (ESRD) in the USA and worldwide. Recent experimental and clinical data suggest that the non-specific phosphodiesterase inhibitor pentoxifylline (PTX) may decrease progression of chronic kidney disease. H...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Rajiv Agarwal, Ian Craig, Domenic J Reda, Grant D Huang, Kimberly Carlson, David J Leehey, Christina Clise, Todd A Conner, James S Kaufman, Robert J Anderson, Douglas Lammie, Jeffrey Huminik, Linda Polzin, Conor McBurney, Nicholas V Emanuele
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BMJ Publishing Group 2021-08-01
Seri Bilgileri:	BMJ Open
Online Erişim:	https://bmjopen.bmj.com/content/11/8/e053019.full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial

Benzer Materyaller